Cabozantinib (C) exposure-response (ER) analysis for the phase 3 CheckMate 9ER (CM 9ER) trial of nivolumab plus cabozantinib (N+C) versus sunitinib (S) in first-line advanced renal cell carcinoma (1L aRCC).
Year: 2021
Type: conference-abstract
Source: Journal of Clinical Oncology
Institutions: The University of Texas MD Anderson Cancer Center, Memorial Sloan Kettering Cancer Center, National Institutes of Health, National Cancer Institute, National Health Service, Queen Mary University of London, The Royal Free Hospital, Cancer Research UK, Barts Cancer Institute, Institut Gustave Roussy, Bristol-Myers Squibb (United States), Exelixis (United States), Dana-Farber Cancer Institute
Language: English
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W3172915078